Histogenics (HSGX) Misses Q2 EPS by 1c
- Wall Street hits new high as post-election rally roars ahead
- ECB to scale back asset buys as it extends to end-2017
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Oil rises above $50 despite doubts over OPEC output cut
- Pre-Open Stock Movers 12/08: (VYGR) (TLRD) (LULU) Higher; (OHRP) (VRNT) (CMTL) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Histogenics (NASDAQ: HSGX) reported Q2 EPS of ($0.61), $0.01 worse than the analyst estimate of ($0.60).
For earnings history and earnings-related data on Histogenics (HSGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Cuts Price Target on SecureWorks Corp. (SCWX) to $13
- Verint Systems (VRNT) Misses Q3 EPS by 10c
- Methode Electronics (MEI) Tops Q2 EPS by 11c; Boosts FY17 EPS Guidance
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!